CLINICAL TRIAL: AUTOLOGOUS EBV SPECIFIC CTLS FOR PROPHYLAXIS AND THERAPY OF EBV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该议定书的目标是： 1.从接受或已经接受实体器官移植(SOT)的个人中产生自体的、EBV特异性的细胞毒性T细胞系(CTL)。 2.对患者实施自体、EBV特异性CTL，以确定这些患者静脉注射的安全性。 3.评价输注CTL的抗病毒和免疫学效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this protocol are: 1. Generate autologous, EBV-specific, cytotoxic T cell lines (CTLs) from individuals receiving or having received a solid organ transplant (SOT). 2. Administer autologous, EBV-specific CTLs to patients, to determine the safety of intravenous injections in these individuals. 3. Evaluate the antiviral and immunological efficacy of the infused CTLs.